Moderna Stock Pops on Surprise Earnings Beat

An unexpected profit and promising news on a deal with the EU boosted Moderna stock.

moderna stock 3d illustration of apart of RNA chain from which the deoxyribonucleic acid or DNA is composed
(Image credit: Getty Images)

Shares in Moderna (MRNA) rose smartly Thursday after the COVID-19 vaccine maker reported better-than-expected earnings and said it was in "active supply discussions" with the European Union.

Explosive demand for the biotechnology firm's coronavirus vaccine allowed MRNA stock to generate outstanding returns during the first year-and-a-half of the pandemic. Shares peaked almost two years ago, however, as global vaccination rates rose and new COVID-19 cases tapered off. As a result, Moderna stock has lost about a quarter of its value in 2023 alone. 

The company's coronavirus vaccine is its only marketable product. As such, Moderna is racing to develop and bring new drugs to market in order to find growth in the post-pandemic era. 

Subscribe to Kiplinger’s Personal Finance

Be a smarter, better informed investor.

Save up to 74%
https://cdn.mos.cms.futurecdn.net/hwgJ7osrMtUWhk5koeVme7-200-80.png

Sign up for Kiplinger’s Free E-Newsletters

Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.

Profit and prosper with the best of expert advice - straight to your e-mail.

Sign up

For the first quarter ended March 31, Moderna reported net income of $79 million, or 19 cents per share. Although that represented a 98% decrease from  net income of $3.7 billion, or $8.58 per share, recorded in last year's Q1, the results easily topped Wall Street estimates. Indeed, analysts surveyed by S&P Global Market Intelligence forecast Moderna to post a net loss of $1.75 a share.

Total revenue fell 69% to $1.9 billion from $6.1 billion in last year's first quarter. Analysts were looking for Moderna to report revenue of $1.2 billion. The company beat the Street's top-line forecast thanks to revenue deferred from 2022.

Moderna vaccine launches on tap

vaccine production vials

(Image credit: Getty Images)

Moderna has next generation COVID-19 vaccines under development, as well as vaccinations for influenza and respiratory syncytial virus (RSV). Other areas of research include immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. 

"Importantly, Moderna is preparing for six major vaccine launches from its respiratory franchise, with expected annual sales of $8 billion to $15 billion by 2027," notes Lee Brown, global sector lead for healthcare at research firm Third Bridge. "The company also plans to begin a Phase 3 trial of mRNA-4157, an individualized neoantigen therapy (INT) in combination with Keytruda for melanoma. mRNA-4157 has the potential to profoundly change the treatment of melanoma."

For now, however, Moderna remains a one-trick COVID-19 vaccine pony. Helpfully, it gave investors a shot of good news on that front following its earnings report. 

Moderna CEO Stéphane Bancel said the company is in discussions with the European Union to supply Europe with vaccines for the fall of 2023 – a time when new coronavirus cases are expected to pick up. MRNA shareholders were deeply concerned by media reports surfacing early this week that Moderna could be shut out of the European COVID-19 vaccine market. 

MRNA stock added more than 6% at one point in early intraday trading, but it still has a long way to go to reclaim anything like its all-time highs. Shares have lost almost three-quarters of their value since setting a record close in August 2021.

stock price chart for Moderna stock

(Image credit: YCharts)

Although the selloff has made the valuation more attractive, Wall Street remains somewhat split on whether MRNA stock offers a good entry point. Of the 21 analysts covering the stock surveyed by S&P Global Market Intelligence, six call it a Strong Buy, five say Buy, nine have it at Hold and one says Sell. That works out to a consensus recommendation of Buy, with mixed conviction.

Analysts' price targets also reflect widely different outcomes. Although the Street's average price target of $218.88 gives MRNA stock implied upside of 60% in the next year or so, those targets range from a high of $430 a share to a low of $93. Should the Street's most bearish forecast come to pass, MRNA would fall roughly 30% from current levels. 

Dan Burrows
Senior Investing Writer, Kiplinger.com

Dan Burrows is Kiplinger's senior investing writer, having joined the august publication full time in 2016.


A long-time financial journalist, Dan is a veteran of SmartMoney, MarketWatch, CBS MoneyWatch, InvestorPlace and DailyFinance. He has written for The Wall Street Journal, Bloomberg, Consumer Reports, Senior Executive and Boston magazine, and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among other publications. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange and hosted a weekly video segment on equities.


Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.


In his current role at Kiplinger, Dan writes about equities, fixed income, currencies, commodities, funds, macroeconomics, demographics, real estate, cost of living indexes and more.


Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.


Disclosure: Dan does not trade stocks or other securities. Rather, he dollar-cost averages into cheap funds and index funds and holds them forever in tax-advantaged accounts.